Related references
Note: Only part of the references are listed.Short Preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
Marta Guix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse
Katharina Pachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
Ian E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines
D. W. Rusnak et al.
CELL PROLIFERATION (2007)
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer
David R. Shaffer et al.
CLINICAL CANCER RESEARCH (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
A Polychronis et al.
LANCET ONCOLOGY (2005)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor
AR Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol
R Leake et al.
JOURNAL OF CLINICAL PATHOLOGY (2000)
Share Paper
